Use of Additional Doses of 2024–2025 COVID-19 Vaccine in Adults Aged ≥65 Years and Persons Aged ≥6 Months With Moderate or Severe Immunocompromise
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
MMWR. Morbidity and Mortality Weekly Report